A new urine-based test, MyProstateScore2.0 (MPS2), has been developed to detect high-grade prostate cancer, potentially reducing unnecessary biopsies by 35-42%. The test looks at 18 different genes linked to high-grade prostate cancer and has shown a high degree of sensitivity, with 95% accuracy for prostate cancers of grade group 2 or greater and 99% for grade group 3 or greater.
Performance of the MPS2 Test
The MPS2 test has demonstrated a high degree of sensitivity, with 95% accuracy for prostate cancers of grade group 2 or greater and 99% for grade group 3 or greater. This means that the test is able to accurately identify the majority of high-grade prostate cancers, which are the most aggressive and potentially life-threatening forms of the disease.
Reducing Unnecessary Biopsies
By utilizing the MPS2 test, it is estimated that the number of unnecessary biopsies can be reduced by 35-42%. This is a significant benefit, as prostate biopsies can be invasive and carry a risk of complications, such as infection and bleeding. Reducing the number of unnecessary biopsies can improve patient comfort, reduce healthcare costs, and free up resources for those who truly need further diagnostic testing.